Dr Roselle Herring BSc, MB BS, MD, FRCP (UK)

Essex Endocrine Clinic is a resource portal for the private practice of Dr Roselle Herring. Her main private practice is at the Spire Wellesley Hospital in Southend-on-Sea, Essex. 

Dr Roselle Herring is a Consultant in Diabetes and Endocrinology and General Medicine at the Mid South Essex Trust. Her special interests include weight loss management, diabetes (Type 1, Type 2 and Type 3c diabetes), thyroid disorders, adrenal and pituitary disorders, metabolic medicine, reproductive hormones and calcium disorders. 

She has been awarded a National Fellowship in Obesity for the Association for the Study of Obesity and is lead clinician for the Essex Tier 3 Obesity Service.

Membership of other Professional and Learned Societies

• Diabetes UK (DUK)
• Association of British Clinical Diabetologists (ABCD)
• Royal College of Physicians, London
• Association for Study of Obesity

Professional Qualifications

• FRCP (UK) Royal College of Physicians, London 
• MD University of Surrey   
• Postgraduate Certificate in Medical Education Warwick University  
• Institute of Leadership and Management level 5 Award Institute of Leadership and Management 
• MRCP (UK)  Royal College of Physicians, London 
• MB BS St Bartholomew’s and Royal London School of Medicine and Dentistry University of London   
• BSc Basic Medical Science with Physiology 
• Queen Mary and Westfield, University of London   

Over the span of Roselle’s medical career she has published extensively in many peer reviewed medical journals.  A selection of recent published articles is set out below:

Herring RA, Parsons I, Shojaee-Moradie F, Stevenage M, Jackson N, Manders R, Umpleby AM, Fielding BA, Davies M, Russell-Jones DL. Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormone Responses to Exercise. J Clin Endocrinol Metab. 2023 Mar 10;108(4):888-896. 

Herring R, Shojaee-Moradie F, Stevenage M et al, The SGLT2inhibitor, dapagliflozin increases the oxidation of ingested fatty acids to ketones in type 2 diabetes. Diabetes Care 2022 June:45 (6) 1408-1415

Russell-Jones DL and Herring R. 100 years of physiology, discrimination and wonder. Diabetic Medicine 2021 July. Vol 38 (12) 

Garden G, Hunt D, Mackie K, Tuthil K, Griffith H, Russell-Jones DL. Herring R. HbA1c and hypoglycaemia outcomes for people with type 1 diabetes due to the introduction of a single-day structured education programme and flash glucose monitoring. British Journal of Diabetes. Feb 2021. 

Herring R, Shojaee-Moradie F, Garesse R et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes, Diabetes Care 2020 Sep;43(9):2128-2136

Wallner M, Andrabi S, Russell-Jones DL, Herring R. Changing inpatient diabetes care in a district general hospital. Br J Diabetes 2019; 19:49-52

Herring R, Russell-Jones DL, SGLT2 inhibitors in type 1 diabetes: Is this the future? Diabetic Medicine July 2018;35(12):1642-1643

Herring R, Russell-Jones DL, Lessons for modern insulin development. Diabetic Medicine May 2018 Oct;35(10):1320-1328

Walsh, S, Herring, R, Griffiths, H, Kohls-Gatzo, J, Davidson S. Coordinating care in acute diabetes foot problems: no mean feet! BJD. April 2016. 16(2): 65-68

Herring R, Knight R, Shojaee-Moradie F, Johnsen S, Umpleby AM, Jackson N, Jones R, Dijk DJ, Russell-Jones DL. Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalopathy in type 1 diabetes. Diabetes Obes Metab. 2015 Nov;17(11):1100-3